<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688802</url>
  </required_header>
  <id_info>
    <org_study_id>OPP-005</org_study_id>
    <nct_id>NCT03688802</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study)</brief_title>
  <official_title>A Single-Center, Randomized, Controlled, Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oyster Point Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oyster Point Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray&#xD;
      as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult&#xD;
      subjects with DED.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change in goblet cell area from Pre-Treatment to Post-Treatment</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>mean change in meibomian gland area from Pre-Treatment to Post-Treatment</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>mean change in goblet cell perimeter from Pre-Treatment to Post-Treatment</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>OC-01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC-01</intervention_name>
    <description>OC-01</description>
    <arm_group_label>OC-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have used and/or desired to use an artificial tear substitute for dry eye symptoms&#xD;
             within 6 months prior to visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such&#xD;
             as blepharoplasty) in either eye within three months or refractive surgery (e.g.&#xD;
             laser-assisted in-situ keratomileusis, laser epithelial keratomileusis,&#xD;
             photorefractive keratectomy or corneal implant) within twelve months of Visit 1&#xD;
&#xD;
          -  Have a history or presence of any ocular disorder or condition in either eye that&#xD;
             would, in the opinion of the Investigator, likely interfere with the interpretation of&#xD;
             the study results or participant safety such as significant corneal or conjunctival&#xD;
             scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis,&#xD;
             or inflammation not associated with dry eye; anterior (epithelial) basement membrane&#xD;
             corneal dystrophy or other clinically significant corneal dystrophy or degeneration;&#xD;
             ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring&#xD;
             treatment and mild meibomian gland disease that are typically associated with DED are&#xD;
             allowed.&#xD;
&#xD;
          -  Have a systemic condition or disease not stabilized or judged by the Investigator to&#xD;
             be incompatible with participation in the study or with the lengthier assessments&#xD;
             required by the study (e.g., current systemic infection, uncontrolled autoimmune&#xD;
             disease, uncontrolled immunodeficiency disease, history of myocardial infarction or&#xD;
             heart disease, etc.)&#xD;
&#xD;
          -  Have a known hypersensitivity to any of the procedural agents or study drug components&#xD;
&#xD;
          -  Have any condition or history that, in the opinion of the investigator, may interfere&#xD;
             with study compliance, outcome measures, safety parameters, and/or the general medical&#xD;
             condition of the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tufts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <disposition_first_submitted>January 26, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 28, 2021</disposition_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 10, 2021</submitted>
    <returned>October 7, 2021</returned>
    <submitted>November 2, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

